22 January 2014 Press releases

GvW Graf von Westphalen advises Venn Life Sciences on the acquisition of shares in CRM clinical trials

With GvW Graf von Westphalen’s support, Venn Life Sciences Holdings plc has acquired pharmaceutical research company CRM clinical trials GmbH by way of an asset deal.

English company Venn Life Sciences Holdings plc is listed at the London Stock Exchange (AIM) and has mainly been dealing with the implementation of pharmaceutical studies for more than 24 years. Up to now, the contract research organization which is acting throughout Europe has not yet been active in Germany.

Through the acquisition of North Rhine Westphalia-based CRM clinical trials GmbH, Venn Life Sciences intends to establish itself in the German market. CRM clinical trials is a mid-size pharmaceutical consulting company with longstanding experience in the planning and implementation of clinical investigations. After the acquisition, Venn Life Sciences will have operations in more than seven European countries.

Venn Life Sciences was advised on this transaction by Frankfurt-based partner Eric Messenzehl and his associate Benjamin Schwarzfischer (both commercial and corporate law, Frankfurt). They were supported by Karsten Kujath (labour law, Frankfurt).

Stay informed

You don't want to miss any more of the latest legal developments? And be invited to our events? Then register here.